Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)

Supplementary Information to accompany and support the manuscript: Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.伴随并支持手稿的补充信息：针对中至重度特应性皮炎成人患者的特拉洛库单抗长期2年安全性及有效性研究：ECZTEND开放标签扩展试验的中期分析。